<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36963989</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1681</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Blood reviews</Title><ISOAbbreviation>Blood Rev</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A role for viruses.</ArticleTitle><Pagination><StartPage>101075</StartPage><MedlinePgn>101075</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.blre.2023.101075</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0268-960X(23)00036-X</ELocationID><Abstract><AbstractText>ME/CFS is a debilitating chronic condition that often develops after viral or bacterial infection. Insight from the study of Long COVID/Post Acute Sequelae of COVID-19 (PASC), the post-viral syndrome associated with SARS-CoV-2 infection, might prove to be useful for understanding pathophysiological mechanisms of ME/CFS. Disease presentation is similar between the two conditions, and a subset of Long COVID patients meet the diagnostic criteria for ME/CFS. Since Long COVID is characterized by significant vascular pathology - including endothelial dysfunction, coagulopathy, and vascular dysregulation - the question of whether or not the same biological abnormalities are of significance in ME/CFS arises. Cardiac abnormalities have for a while now been documented in ME/CFS cohorts, with recent studies demonstrating major deficits in cerebral blood flow, and hence vascular dysregulation. A growing body of research is demonstrating that ME/CFS is accompanied by platelet hyperactivation, anomalous clotting, a procoagulant phenotype, and endothelial dysfunction. Endothelial damage and dysregulated clotting can impair substance exchange between blood and tissues, and result in hypoperfusion, which may contribute to the manifestation of certain ME/CFS symptoms. Here we review the ME/CFS literature to summarize cardiovascular and haematological findings documented in patients with the condition, and, in this context, briefly discuss the potential role of previously-implicated pathogens. Overall, cardiac and haematological abnormalities are present within ME/CFS cohorts. While atherosclerotic heart disease is not significantly associated with ME/CFS, suboptimal cardiovascular function defined by reduced cardiac output, impaired cerebral blood flow, and vascular dysregulation are, and these abnormalities do not appear to be influenced by deconditioning. Rather, these cardiac abnormalities may result from dysfunction in the (autonomic) nervous system. Plenty of recently published studies are demonstrating significant platelet hyperactivity and endothelial dysfunction in ME/CFS, as well as anomalous clotting processes. It is of particular importance to determine to what extent these cardiovascular and haematological abnormalities contribute to symptom severity, and if these two systems can be targeted for therapeutic purposes. Viral reservoirs of herpesviruses exist in ME/CFS, and most likely contribute to cardiovascular and haematological dysfunction directly or indirectly. This review highlights the potential of studying cardiac functioning, the vasculature, and coagulation system in ME/CFS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Jean M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland 7602, South Africa. Electronic address: 18131018@sun.ac.za.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kell</LastName><ForeName>Douglas B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland 7602, South Africa; Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St, Liverpool L69 7ZB, UK; The Novo Nordisk Foundation Centre for Biosustainability, Building 220, Chemitorvet 200, Technical University of Denmark, 2800 Kongens Lyngby, Denmark. Electronic address: dbk@liv.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pretorius</LastName><ForeName>Etheresia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland 7602, South Africa; Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St, Liverpool L69 7ZB, UK. Electronic address: resiap@sun.ac.za.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Blood Rev</MedlineTA><NlmUniqueID>8708558</NlmUniqueID><ISSNLinking>0268-960X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Endothelial dysfunction</Keyword><Keyword MajorTopicYN="N">Haematological system</Keyword><Keyword MajorTopicYN="N">Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>23</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36963989</ArticleId><ArticleId IdType="pmc">PMC10027292</ArticleId><ArticleId IdType="doi">10.1016/j.blre.2023.101075</ArticleId><ArticleId IdType="pii">S0268-960X(23)00036-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cortes Rivera M., Mastronardi C., Silva-Aldana C.T., Arcos-Burgos M., Lidbury B.A. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics (Basel). 2019:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787585</ArticleId><ArticleId IdType="pubmed">31394725</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., van de Sande M.I., De Meirleir K.L., Klimas N.G., Broderick G., Mitchell T., et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270:327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S., Nora-Krukle Z., Henning N., Eliassen E., Shikova E., Harrer T., et al. Chronic viral infections in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J Transl Med. 2018;16:268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference><Reference><Citation>Underhill R.A. Myalgic encephalomyelitis, chronic fatigue syndrome: an infectious disease. Med Hypotheses. 2015;85:765&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">26604026</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., Mirin A.A. Updating the National Academy of Medicine ME/CFS prevalence and economic impact figures to account for population growth and inflation. Fatigue: Biomedicine, Health &amp; Behavior. 2021;9:9&#x2013;13.</Citation></Reference><Reference><Citation>Mirin A.A., Dimmock M.E., Jason L.A. Updated ME/CFS prevalence estimates reflecting post-COVID increases and associated economic costs and funding implications. Fatigue: Biomedicine, Health &amp; Behavior. 2022:1&#x2013;11.</Citation></Reference><Reference><Citation>Petracek L.S., Suskauer S.J., Vickers R.F., Patel N.R., Violand R.L., Swope R.L., et al. Adolescent and Young adult ME/CFS after confirmed or probable COVID-19. Front Med (Lausanne). 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116546</ArticleId><ArticleId IdType="pubmed">33996867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Hanitsch L.G., Zoller T., et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. 2022;13:5104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Zoller T., Steinbeis F., et al. Chronic COVID-19 Syndrome and Chronic Fatigue Syndrome (ME/CFS) following the first pandemic wave in Germany &#x2013; a first analysis of a prospective observational study. medRxiv. 2021 2021.02.06.21249256.</Citation></Reference><Reference><Citation>Tokumasu K., Honda H., Sunada N., Sakurada Y., Matsuda Y., Yamamoto K., et al. 2022. Clinical Characteristics of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Diagnosed in Patients with Long COVID. Medicina (Kaunas) p. 58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9325226</ArticleId><ArticleId IdType="pubmed">35888568</ArticleId></ArticleIdList></Reference><Reference><Citation>Falk Hvidberg M., Brinth L.S., Olesen A.V., Petersen K.D., Ehlers L. The health-related quality of life for patients with Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) PloS One. 2015;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492975</ArticleId><ArticleId IdType="pubmed">26147503</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon L., Reeves W.C. Factors influencing the diagnosis of chronic fatigue syndrome. Arch Intern Med. 2004;164:2241&#x2013;2245.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534161</ArticleId></ArticleIdList></Reference><Reference><Citation>Araja D., Berkis U., Lunga A., Murovska M. Shadow burden of undiagnosed Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on society: retrospective and prospective&#x2014;in light of COVID-19. J Clin Med. 2021;10:3017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8303374</ArticleId><ArticleId IdType="pubmed">34300183</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannan K.L., Berg D.E., Baumzweiger W., Harrison H.H., Berg L.H., Ramirez R., et al. Activation of the coagulation system in gulf war illness: a potential pathophysiologic link with chronic fatigue syndrome. A laboratory approach to diagnosis. Blood Coagul Fibrinolysis. 2000;11:673&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">11085289</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda S., Kuratsune H., Kajimoto O., Watanabe Y. Fatigue-related problem scale for better understanding of pathophysiology of chronic fatigue syndrome and fibromyalgia. Advances in Neuroimmune Biology. 2012;3:361&#x2013;366.</Citation></Reference><Reference><Citation>Helliwell A.M., Sweetman E.C., Stockwell P.A., Edgar C.D., Chatterjee A., Tate W.P. Changes in DNA methylation profiles of Myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions. Clin Epigenetics. 2020;12:167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7641803</ArticleId><ArticleId IdType="pubmed">33148325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth K., Scheibenbogen C. A unifying hypothesis of the pathophysiology of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): recognitions from the finding of autoantibodies against ss2-adrenergic receptors. Autoimmun Rev. 2020;19</Citation><ArticleIdList><ArticleId IdType="pubmed">32247028</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu L., Valencia I.J., Garvert D.W., Montoya J.G. Onset patterns and course of Myalgic encephalomyelitis/chronic fatigue syndrome. Front Pediatr. 2019;7:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6370741</ArticleId><ArticleId IdType="pubmed">30805319</ArticleId></ArticleIdList></Reference><Reference><Citation>Bested A.C., Marshall L.M. Review of Myalgic encephalomyelitis/chronic fatigue syndrome: an evidence-based approach to diagnosis and management by clinicians. Rev Environ Health. 2015;30:223&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">26613325</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton E.W. Beyond Myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015;313:1101&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25668027</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds G.K., Lewis D.P., Richardson A.M., Lidbury B.A. Comorbidity of postural orthostatic tachycardia syndrome and chronic fatigue syndrome in an Australian cohort. J Intern Med. 2014;275:409&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">24206536</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitag H., Szklarski M., Lorenz S., Sotzny F., Bauer S., Philippe A., et al. Autoantibodies to Vasoregulative G-protein-coupled receptors correlate with symptom severity, autonomic dysfunction and disability in Myalgic encephalomyelitis/chronic fatigue syndrome. J Clin Med. 2021:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8397061</ArticleId><ArticleId IdType="pubmed">34441971</ArticleId></ArticleIdList></Reference><Reference><Citation>Costigan A., Elliott C., McDonald C., Newton J.L. Orthostatic symptoms predict functional capacity in chronic fatigue syndrome: implications for management. QJM. 2010;103:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">20534655</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton D.J., Kennedy G., Chan K.K., Lang C.C., Belch J.J., Khan F. Large and small artery endothelial dysfunction in chronic fatigue syndrome. Int J Cardiol. 2012;154:335&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">22078396</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambras T., Castro-Marrero J., Zaragoza M.C., Diez-Noguera A., Alegre J. Circadian rhythm abnormalities and autonomic dysfunction in patients with chronic fatigue syndrome/Myalgic encephalomyelitis. PloS One. 2018;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5991397</ArticleId><ArticleId IdType="pubmed">29874259</ArticleId></ArticleIdList></Reference><Reference><Citation>Missailidis D., Annesley S.J., Fisher P.R. Pathological mechanisms underlying Myalgic encephalomyelitis/chronic fatigue syndrome. Diagnostics (Basel) 2019:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787592</ArticleId><ArticleId IdType="pubmed">31330791</ArticleId></ArticleIdList></Reference><Reference><Citation>van Campen C., Verheugt F.W.A., Rowe P.C., Visser F.C. Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: a quantitative, controlled study using Doppler echography. Clin Neurophysiol Pract. 2020;5:50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7044650</ArticleId><ArticleId IdType="pubmed">32140630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth K.J., Scheibenbogen C. Pathophysiology of skeletal muscle disturbances in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J Transl Med. 2021;19:162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058748</ArticleId><ArticleId IdType="pubmed">33882940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia J., Chia A., Voeller M., Lee T., Chang R. Acute enterovirus infection followed by Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and viral persistence. J Clin Pathol. 2010;63:165&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">19828908</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox B.S., Alharshawi K., Mena-Palomo I., Lafuse W.P., Ariza M.E. EBV/HHV-6A dUTPases contribute to Myalgic encephalomyelitis/chronic fatigue syndrome pathophysiology by enhancing TFH cell differentiation and extrafollicular activities. JCI. Insight. 2022:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9220958</ArticleId><ArticleId IdType="pubmed">35482424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M.E. Myalgic encephalomyelitis/chronic fatigue syndrome: the human herpesviruses are Back! Biomolecules. 2021:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7912523</ArticleId><ArticleId IdType="pubmed">33572802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasimir F., Toomey D., Liu Z., Kaiping A.C., Ariza M.E., Prusty B.K. Tissue specific signature of HHV-6 infection in ME/CFS. Front Mol Biosci. 2022:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9795011</ArticleId><ArticleId IdType="pubmed">36589231</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Piazza M., Boner A.L., Bellanti J.A. Long COVID: a proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma Proc. 2022;43:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9106095</ArticleId><ArticleId IdType="pubmed">35524358</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., Ramelli S.C., Grazioli A., Chung J.-Y., Singh M., Yinda C.K., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Francisco E.B., Yogendra R., Long E., Pise A., Rodrigues H., et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in Post-acute sequelae of COVID-19 (PASC) up to 15 months Post-infection. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo G.D., Lazarini F., Levallois S., Hautefort C., Michel V., Larrous F., et al. COVID-19&#x2013;related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. 2021;13 eabf8396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa D.C., Tannock C., Brostoff J. Brainstem perfusion is impaired in chronic fatigue syndrome. Qjm. 1995;88:767&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">8542261</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Julin P., Li T.Q. Limbic perfusion is reduced in patients with Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Tomography. 2021;7:675&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8628916</ArticleId><ArticleId IdType="pubmed">34842817</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G., Maes M. Mitochondria and immunity in chronic fatigue syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2020;103</Citation><ArticleIdList><ArticleId IdType="pubmed">32470498</ArticleId></ArticleIdList></Reference><Reference><Citation>Missailidis D., Annesley S.J., Allan C.Y., Sanislav O., Lidbury B.A., Lewis D.P., et al. An isolated complex V inefficiency and dysregulated mitochondrial function in immortalized lymphocytes from ME/CFS patients. Int J Mol Sci. 2020;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036826</ArticleId><ArticleId IdType="pubmed">32041178</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden S., Maksoud R., Eaton-Fitch N., Cabanas H., Staines D., Marshall-Gradisnik S. A systematic review of mitochondrial abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease. J Transl Med. 2020;18:290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392668</ArticleId><ArticleId IdType="pubmed">32727475</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes J.M., Kruger A., Proal A., Kell D.B., Pretorius E. The occurrence of Hyperactivated platelets and Fibrinaloid microclots in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Pharmaceuticals. 2022;15:931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9413879</ArticleId><ArticleId IdType="pubmed">36015078</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer J.H., Berg D. Hypercoaguable state associated with active human Herpesvirus-6 (HHV-6) viremia in patients with chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome. 2001;8:111&#x2013;116.</Citation></Reference><Reference><Citation>Kell D.B., Pretorius E. The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochem J. 2022;479:1653&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484810</ArticleId><ArticleId IdType="pubmed">36043493</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth K.J., Scheibenbogen C., Paul F. An attempt to explain the neurological symptoms of Myalgic encephalomyelitis/chronic fatigue syndrome. J Transl Med. 2021;19:471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8607226</ArticleId><ArticleId IdType="pubmed">34809664</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Pathogens hijack host cell metabolism: intracellular infection as a driver of the Warburg effect in cancer and other chronic inflammatory conditions. Immunometabolism. 2021;3</Citation></Reference><Reference><Citation>Shan Z.Y., Kwiatek R., Burnet R., Del Fante P., Staines D.R., Marshall-Gradisnik S.M., et al. Progressive brain changes in patients with chronic fatigue syndrome: a longitudinal MRI study. J Magn Reson Imaging. 2016;44:1301&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111735</ArticleId><ArticleId IdType="pubmed">27123773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatomi Y., Kuratsune H., Watanabe Y., et al. Brain Nerve. 2018;70:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">29348371</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelmeyer A., He J., Maclachlan L., Watson S., Gallagher P., Newton J.L., et al. Grey and white matter differences in chronic fatigue syndrome - a voxel-based morphometry study. Neuroimage Clin. 2018;17:24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5633338</ArticleId><ArticleId IdType="pubmed">29021956</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Maes M. A neuro-immune model of Myalgic encephalomyelitis/chronic fatigue syndrome. Metab Brain Dis. 2013;28:523&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">22718491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay A. A neuro-inflammatory model can explain the onset, symptoms and flare-ups of Myalgic encephalomyelitis/chronic fatigue syndrome. J Prim Health Care. 2019;11:300&#x2013;307.</Citation></Reference><Reference><Citation>Morrow A.K., Malone L.A., Kokorelis C., Petracek L.S., Eastin E.F., Lobner K.L., et al. Long-term COVID 19 sequelae in adolescents: the overlap with orthostatic intolerance and ME/CFS. Curr Pediatr Rep. 2022:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906524</ArticleId><ArticleId IdType="pubmed">35287333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong T.L., Weitzer D.J. 2021. Long COVID and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas) p. 57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Ismail M.Y., Diamond A., Kapoor S., Arafah Y., Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305763</ArticleId><ArticleId IdType="pubmed">32788101</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262324</ArticleId><ArticleId IdType="pubmed">32271988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang M., Li M.D., Buch K., Yoon B.C., Applewhite B.P., Leslie-Mazwi T.M., et al. Risk of acute cerebrovascular events in patients with COVID-19 infection. AJNR Am J Neuroradiol. 2020;41 E92-E3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658821</ArticleId><ArticleId IdType="pubmed">32855192</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Venter C., Laubscher G.J., Lourens P.J., Steenkamp J., Kell D.B. Prevalence of readily detected amyloid blood clots in &#x2018;unclotted&#x2019; type 2 diabetes mellitus and COVID-19 plasma: a preliminary report. Cardiovasc Diabetol. 2020;19:193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670290</ArticleId><ArticleId IdType="pubmed">33203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffke M., Freitag H., Rudolf G., Seifert M., Doehner W., Scherbakov N., et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) J Transl Med. 2022;20:138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938726</ArticleId><ArticleId IdType="pubmed">35317812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479:537&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.S., Lacerda E.M., Nacul L., Kingdon C.C., Norris J., O&#x2019;Boyle S., et al. Salivary DNA loads for human herpesviruses 6 and 7 are correlated with disease phenotype in Myalgic encephalomyelitis/chronic fatigue syndrome. Front Med (Lausanne) 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8378328</ArticleId><ArticleId IdType="pubmed">34422848</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikova E., Reshkova V., Kumanova Capital A.C., Raleva S., Alexandrova D., Capo N., et al. Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with Myalgic small ie, Cyrillicncephalomyelitis/chronic fatigue syndrome. J Med Virol. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687071</ArticleId><ArticleId IdType="pubmed">32129496</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., Corradi K., Gress S., Williams S., Torres-Harding S. Causes of death among patients with chronic fatigue syndrome. Health Care Women Int. 2006;27:615&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">16844674</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Coenzyme Q10 deficiency in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett. 2009;30:470&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">20010505</ArticleId></ArticleIdList></Reference><Reference><Citation>McManimen S.L., Devendorf A.R., Brown A.A., Moore B.C., Moore J.H., Jason L.A. Mortality in patients with Myalgic encephalomyelitis and chronic fatigue syndrome. Fatigue. 2016;4:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218818</ArticleId><ArticleId IdType="pubmed">28070451</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond J., Nielsen T., Hodges L. Effects of post-exertional malaise on markers of arterial stiffness in individuals with Myalgic encephalomyelitis/chronic fatigue syndrome. Int J Environ Res Public Health. 2021;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7957494</ArticleId><ArticleId IdType="pubmed">33671082</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B., Bluemke D.A., L&#xfc;scher T.F., Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43:1157&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Twisk F.N. Why Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&amp;NS) pathways may explain cardiovascular disorders in ME/CFS. Neuro Endocrinol Lett. 2009;30:677&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">20038921</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo J.C., Cordobilla B., Ferrer R., Giralt M., Alegre-Mart&#xed;n J., Castro-Marrero J. Are circulating fibroblast growth factor 21 and N-terminal prohormone of brain natriuretic peptide promising novel biomarkers in Myalgic encephalomyelitis/chronic fatigue syndrome? Antioxid Redox Signal. 2021;34:1420&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pubmed">33353469</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased plasma peroxides as a marker of oxidative stress in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Med Sci Monit. 2011;17 Sc11&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539515</ArticleId><ArticleId IdType="pubmed">21455120</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong C.W., McGregor N.R., Lewis D.P., Butt H.L., Gooley P.R. Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients. Metabolomics. 2015;11:1626&#x2013;1639.</Citation></Reference><Reference><Citation>Gottschalk G., Peterson D., Knox K., Maynard M., Whelan R.J., Roy A. Elevated ATG13 in serum of patients with ME/CFS stimulates oxidative stress response in microglial cells via activation of receptor for advanced glycation end products (RAGE) Molecular and Cellular Neuroscience. 2022;120</Citation><ArticleIdList><ArticleId IdType="pubmed">35487443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood E., Hall K.H., Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in Myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 &#x2018;long-haulers&#x2019;? Chronic Diseases and Translational Medicine. 2021;7:14&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680046</ArticleId><ArticleId IdType="pubmed">33251031</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Maes M. Mitochondrial dysfunctions in Myalgic encephalomyelitis / chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis. 2014;29:19&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">24557875</ArticleId></ArticleIdList></Reference><Reference><Citation>Patarca R. Cytokines and chronic fatigue syndrome. Ann N Y Acad Sci. 2001;933:185&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000020</ArticleId></ArticleIdList></Reference><Reference><Citation>Spence V.A., Kennedy G., Belch J.J., Hill A., Khan F. Low-grade inflammation and arterial wave reflection in patients with chronic fatigue syndrome. Clin Sci (Lond) 2008;114:561&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">18031285</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Twisk F.N., Kubera M., Ringel K. Evidence for inflammation and activation of cell-mediated immunity in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-&#x3b1;, PMN-elastase, lysozyme and neopterin. J Affect Disord. 2012;136:933&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">21975140</ArticleId></ArticleIdList></Reference><Reference><Citation>Giloteaux L., Goodrich J.K., Walters W.A., Levine S.M., Ley R.E., Hanson M.R. Reduced diversity and altered composition of the gut microbiome in individuals with Myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918027</ArticleId><ArticleId IdType="pubmed">27338587</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonato M., Dall&#x2019;Acqua S., Zilli C., Sut S., Tenconi R., Gallo N., et al. Tryptophan metabolites, cytokines, and fatty acid binding protein 2 in Myalgic encephalomyelitis/chronic fatigue syndrome. Biomedicines. 2021:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8615774</ArticleId><ArticleId IdType="pubmed">34829952</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason L.A., Gaglio C.L., Furst J., Islam M., Sorenson M., Conroy K.E., et al. Cytokine network analysis in a community-based pediatric sample of patients with Myalgic encephalomyelitis/chronic fatigue syndrome. Chronic Illn. 2022 17423953221101606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9666669</ArticleId><ArticleId IdType="pubmed">35570777</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsj&#xf6; M.A., Olsson G.L., Wicksell R.K., Alving K., Holmstr&#xf6;m L., Andreasson A. The role of low-grade inflammation in ME/CFS (Myalgic encephalomyelitis/chronic fatigue syndrome) - associations with symptoms. Psychoneuroendocrinology. 2020;113</Citation><ArticleIdList><ArticleId IdType="pubmed">31901625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Vernon S.D., Jeys P., Ali W., Campos A., Unutmaz D., et al. Hemodynamics during the 10-minute NASA lean test: evidence of circulatory decompensation in a subset of ME/CFS patients. J Transl Med. 2020;18:314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429890</ArticleId><ArticleId IdType="pubmed">32799889</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C., Jin Z., Takei Y., Hasegawa T., Koshaka S., Palmieri V., et al. Arterial wave reflection and subclinical left ventricular systolic dysfunction. J Hypertens. 2011;29:574&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039083</ArticleId><ArticleId IdType="pubmed">21169863</ArticleId></ArticleIdList></Reference><Reference><Citation>Dworkin H.J., Lawrie C., Bohdiewicz P., Lerner A.M. Abnormal left ventricular myocardial dynamics in eleven patients with chronic fatigue syndrome. Clin Nucl Med. 1994;19:675&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">7955743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurwitz B.E., Coryell V.T., Parker M., Martin P., Laperriere A., Klimas N.G., et al. Chronic fatigue syndrome: illness severity, sedentary lifestyle, blood volume and evidence of diminished cardiac function. Clin Sci (Lond) 2009;118:125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">19469714</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart J.M. Chronic fatigue syndrome: comments on deconditioning, blood volume and resulting cardiac function. Clin Sci (Lond) 2009;118:121&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236909</ArticleId><ArticleId IdType="pubmed">19534728</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaak J., Montmerle S., Sundblad P., Linnarsson D. Long-term bed rest-induced reductions in stroke volume during rest and exercise: cardiac dysfunction vs. volume depletion. J Appl Physiol. 2005;98:648&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingsworth K.G., Hodgson T., Macgowan G.A., Blamire A.M., Newton J.L. Impaired cardiac function in chronic fatigue syndrome measured using magnetic resonance cardiac tagging. J Intern Med. 2012;271:264&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627316</ArticleId><ArticleId IdType="pubmed">21793948</ArticleId></ArticleIdList></Reference><Reference><Citation>Miwa K. Cardiac dysfunction and orthostatic intolerance in patients with Myalgic encephalomyelitis and a small left ventricle. Heart Vessels. 2015;30:484&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">24736946</ArticleId></ArticleIdList></Reference><Reference><Citation>van Campen C.M.C., Rowe P.C., Visser F.C. Blood volume status in ME/CFS correlates with the presence or absence of orthostatic symptoms: preliminary results. Frontiers in Pediatrics. 2018:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262290</ArticleId><ArticleId IdType="pubmed">30525014</ArticleId></ArticleIdList></Reference><Reference><Citation>CLMCV Campen, Visser F.C. 2018. The Abnormal Cardiac Index and Stroke Volume Index Changes during a Normal Tilt Table Test in Mecfs Patients Compared to Healthy Volunteers are not Related to Deconditioning.</Citation></Reference><Reference><Citation>van Campen C., Rowe P.C., Visser F.C. Deconditioning does not explain orthostatic intolerance in ME/CFS (Myalgic encephalomyelitis/chronic fatigue syndrome) J Transl Med. 2021;19:193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8097965</ArticleId><ArticleId IdType="pubmed">33947430</ArticleId></ArticleIdList></Reference><Reference><Citation>van Campen C.M.C., Visser F.C. Comparison of the degree of deconditioning in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients with and without orthostatic intolerance. Medical Research Archives. 2022:10.</Citation></Reference><Reference><Citation>Newton J.L., Finkelmeyer A., Petrides G., Frith J., Hodgson T., Maclachlan L., et al. Reduced cardiac volumes in chronic fatigue syndrome associate with plasma volume but not length of disease: a cohort study. Open Heart. 2016;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932290</ArticleId><ArticleId IdType="pubmed">27403329</ArticleId></ArticleIdList></Reference><Reference><Citation>Olimulder M.A., Galjee M.A., Wagenaar L.J., van Es J., van der Palen J., Visser F.C., et al. Chronic fatigue syndrome in women assessed with combined cardiac magnetic resonance imaging. Neth Heart J. 2016;24:709&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120006</ArticleId><ArticleId IdType="pubmed">27561279</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen P.O., von Lueder T.G., Kardel K.R., Lien K. Cardiac dimensions and function are not altered among females with the Myalgic encephalomyelitis/chronic fatigue syndrome. Healthcare (Basel) 2020:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712104</ArticleId><ArticleId IdType="pubmed">33081294</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Mariscal F.M., de la Cruz-Ares S., Torres-Pe&#xf1;a J.D., Alcal&#xe1;-Diaz J.F., Yubero-Serrano E.M., L&#xf3;pez-Miranda J. Coenzyme Q10 and cardiovascular diseases. Antioxidants. 2021;10:906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8229886</ArticleId><ArticleId IdType="pubmed">34205085</ArticleId></ArticleIdList></Reference><Reference><Citation>Littarru G.P., Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007;37:31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">17914161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Kaur H., Devi P., Mohan V. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther. 2009;124:259&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638284</ArticleId></ArticleIdList></Reference><Reference><Citation>Martelli A., Testai L., Colletti A., Cicero A.F.G. Coenzyme Q(10): clinical applications in cardiovascular diseases. Antioxidants (Basel) 2020:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222396</ArticleId><ArticleId IdType="pubmed">32331285</ArticleId></ArticleIdList></Reference><Reference><Citation>Molyneux S.L., Florkowski C.M., George P.M., Pilbrow A.P., Frampton C.M., Lever M., et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52:1435&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">19017509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcin A., Kilinc E., Sagcan A., Kultursay H. Coenzyme Q10 concentrations in coronary artery disease. Clin Biochem. 2004;37:706&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapidze G., Kapanadze S., Dolidze N., Bachutashvili Z., Latsabidze N. Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant coenzyme Q10 and statins. Georgian Med News. 2005;20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15821319</ArticleId></ArticleIdList></Reference><Reference><Citation>Dludla P.V., Orlando P., Silvestri S., Marcheggiani F., Cirilli I., Nyambuya T.M., et al. Coenzyme Q(10) supplementation improves adipokine levels and alleviates inflammation and lipid peroxidation in conditions of metabolic syndrome: a meta-analysis of randomized controlled trials. Int J Mol Sci. 2020;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247332</ArticleId><ArticleId IdType="pubmed">32375340</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic S., Brkic S., Maric D., Mikic A.N. Lipid and protein oxidation in female patients with chronic fatigue syndrome. Arch Med Sci. 2012;8:886&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506242</ArticleId><ArticleId IdType="pubmed">23185200</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Marrero J., Domingo J.C., Cordobilla B., Ferrer R., Giralt M., Sanmart&#xed;n-Senta&#xf1;es R., et al. Does coenzyme Q10 plus selenium supplementation ameliorate clinical outcomes by modulating oxidative stress and inflammation in individuals with Myalgic encephalomyelitis/chronic fatigue syndrome? Antioxid Redox Signal. 2022;36:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057907</ArticleId><ArticleId IdType="pubmed">35229657</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Marrero J., Zaragoz&#xe1; M.C., Domingo J.C., Martinez-Martinez A., Alegre J., von Schacky C. Low omega-3 index and polyunsaturated fatty acid status in patients with chronic fatigue syndrome/Myalgic encephalomyelitis. Prostaglandins Leukot Essent Fatty Acids. 2018;139:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30471769</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente-Cebri&#xe1;n S., Costa A.G.V., Navas-Carretero S., Zabala M., Laiglesia L.M., Mart&#xed;nez J.A., et al. An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases. J Physiol Biochem. 2015;71:341&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">25752887</ArticleId></ArticleIdList></Reference><Reference><Citation>von Schacky C. Omega-3 index and cardiovascular health. Nutrients. 2014;6:799&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942733</ArticleId><ArticleId IdType="pubmed">24566438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanai H., Masui Y., Katsuyama H., Adachi H., Kawaguchi A., Hakoshima M., et al. An improvement of cardiovascular risk factors by Omega-3 polyunsaturated fatty acids. J Clin Med Res. 2018;10:281&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5827911</ArticleId><ArticleId IdType="pubmed">29511415</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain A., Ruppert D., Levine S.M., Hanson M.R. Metabolic profiling of a Myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Mol Biosyst. 2017;13:371&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5365380</ArticleId><ArticleId IdType="pubmed">28059425</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain A., Barupal D.K., Levine S.M., Hanson M.R. Comprehensive circulatory metabolomics in ME/CFS reveals disrupted metabolism of acyl lipids and steroids. Metabolites. 2020;10:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7023305</ArticleId><ArticleId IdType="pubmed">31947545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashi A.A., Davis R.W., Phair R.D. The IDO metabolic trap hypothesis for the Etiology of ME/CFS. Diagnostics. 2019;9:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787624</ArticleId><ArticleId IdType="pubmed">31357483</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibbins-Domingo K., Gupta R., Na B., Wu A.H.B., Schiller N.B., Whooley M.A. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848442</ArticleId><ArticleId IdType="pubmed">17213400</ArticleId></ArticleIdList></Reference><Reference><Citation>Staiger H., Keuper M., Berti L., Hrab&#x11b; de Angelis M., H&#xe4;ring H.-U. Fibroblast growth factor 21&#x2014;metabolic role in mice and men. Endocr Rev. 2017;38:468&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">28938407</ArticleId></ArticleIdList></Reference><Reference><Citation>Schondorf R., Freeman R. The importance of orthostatic intolerance in the chronic fatigue syndrome. Am J Med Sci. 1999;317:117&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim E.-J., Son C.-G. Review of case definitions for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J Transl Med. 2020;18:289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391812</ArticleId><ArticleId IdType="pubmed">32727489</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoad A., Spickett G., Elliott J., Newton J. Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. Qjm. 2008;101:961&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">18805903</ArticleId></ArticleIdList></Reference><Reference><Citation>Miwa K., Fujita M. Small heart syndrome in patients with chronic fatigue syndrome. Clin Cardiol. 2008;31:328&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6653127</ArticleId><ArticleId IdType="pubmed">18636530</ArticleId></ArticleIdList></Reference><Reference><Citation>Miwa K., Fujita M. Cardiac function fluctuates during exacerbation and remission in young adults with chronic fatigue syndrome and &#x201c;small heart&#x201d;. J Cardiol. 2009;54:29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">19632517</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton J.L., Sheth A., Shin J., Pairman J., Wilton K., Burt J.A., et al. Lower ambulatory blood pressure in chronic fatigue syndrome. Psychosom Med. 2009;71:361&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">19297309</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A.A., Jason L.A., Evans M.A., Flores S. Contrasting case definitions: the ME international consensus criteria vs. the Fukuda et al. CFS criteria. N Am J Psychol. 2013;15:103&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215640</ArticleId><ArticleId IdType="pubmed">25364305</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon J., Kim D.-Y., Byun J.-I., Sunwoo J.-S., Lim J.-A., Kim T.-J., et al. Orthostatic intolerance symptoms are associated with depression and diminished quality of life in patients with postural tachycardia syndrome. Health Qual Life Outcomes. 2016;14:144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5059908</ArticleId><ArticleId IdType="pubmed">27729043</ArticleId></ArticleIdList></Reference><Reference><Citation>Roma M., Marden C.L., Flaherty M.A.K., Jasion S.E., Cranston E.M., Rowe P.C. Impaired health-related quality of life in adolescent Myalgic encephalomyelitis/chronic fatigue syndrome: the impact of core symptoms. Front Pediatr. 2019;7:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6385524</ArticleId><ArticleId IdType="pubmed">30828572</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner R., Baraniuk J.N. Orthostatic intolerance in chronic fatigue syndrome. J Transl Med. 2019;17:185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547462</ArticleId><ArticleId IdType="pubmed">31159884</ArticleId></ArticleIdList></Reference><Reference><Citation>van Campen C., Rowe P.C., Visser F.C. 2021. Compression stockings improve cardiac output and cerebral blood flow during tilt testing in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients: A randomized crossover trial. Medicina (Kaunas) p. 58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781100</ArticleId><ArticleId IdType="pubmed">35056360</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S., Kuratsune H., Hidaka Y., Hakariya Y., Tatsumi K.I., Takano T., et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med. 2003;12:225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">12851722</ArticleId></ArticleIdList></Reference><Reference><Citation>Loebel M., Grabowski P., Heidecke H., Bauer S., Hanitsch L.G., Wittke K., et al. Antibodies to &#x3b2; adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. 2016;52:32&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">26399744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bynke A., Julin P., Gottfries C.G., Heidecke H., Scheibenbogen C., Bergquist J. Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic encephalomyelitis (ME) patients - a validation study in plasma and cerebrospinal fluid from two Swedish cohorts. Brain Behav Immun Health. 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8474431</ArticleId><ArticleId IdType="pubmed">34589868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S., Ouchi Y., Nakatsuka D., Tahara T., Mizuno K., Tajima S., et al. Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor. PloS One. 2012;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519853</ArticleId><ArticleId IdType="pubmed">23240035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwig J., Sotzny F., Bauer S., Heidecke H., Riemekasten G., Dragun D., et al. IgG stimulated &#x3b2;2 adrenergic receptor activation is attenuated in patients with ME/CFS. Brain, Behavior, &amp; Immunity - Health. 2020;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8474590</ArticleId><ArticleId IdType="pubmed">34589837</ArticleId></ArticleIdList></Reference><Reference><Citation>Slinger E., Langemeijer E., Siderius M., Vischer H.F., Smit M.J. Herpesvirus-encoded GPCRs rewire cellular signaling. Mol Cell Endocrinol. 2011;331:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">20398729</ArticleId></ArticleIdList></Reference><Reference><Citation>Campen CMCv, Rowe PC, Visser FC. vol. 58. 2022. Orthostatic symptoms and reductions in cerebral blood flow in Long-haul COVID-19 patients: Similarities with Myalgic encephalomyelitis/chronic fatigue syndrome. Medicina; p. 28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8778312</ArticleId><ArticleId IdType="pubmed">35056336</ArticleId></ArticleIdList></Reference><Reference><Citation>Campen CMv, Rowe PC, Visser FC. Reductions in cerebral blood flow can be provoked by sitting in severe Myalgic encephalomyelitis/chronic fatigue syndrome patients. Healthcare. 2020;8:394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712289</ArticleId><ArticleId IdType="pubmed">33050553</ArticleId></ArticleIdList></Reference><Reference><Citation>van Campen C.M.C., Rowe P.C., Visser F.C. Cerebral blood flow remains reduced after tilt testing in Myalgic encephalomyelitis/chronic fatigue syndrome patients. Clin Neurophysiol Pract. 2021;6:245&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8505270</ArticleId><ArticleId IdType="pubmed">34667909</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal B., Kunwar P., Natelson B.H. Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. J Neurol Sci. 2011;301:9&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139492</ArticleId><ArticleId IdType="pubmed">21167506</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissoneault J., Letzen J., Robinson M., Staud R. Cerebral blood flow and heart rate variability predict fatigue severity in patients with chronic fatigue syndrome. Brain Imaging Behav. 2019;13:789&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6274602</ArticleId><ArticleId IdType="pubmed">29855991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiuchi K., Farkas J., Natelson B.H. Patients with chronic fatigue syndrome have reduced absolute cortical blood flow. Clin Physiol Funct Imaging. 2006;26:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16494597</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmaling K.B., Lewis D.H., Fiedelak J.I., Mahurin R., Buchwald D.S. Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. Psychosom Med. 2003;65:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12554824</ArticleId></ArticleIdList></Reference><Reference><Citation>Shungu D.C., Weiduschat N., Murrough J.W., Mao X., Pillemer S., Dyke J.P., et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012;25:1073&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896084</ArticleId><ArticleId IdType="pubmed">22281935</ArticleId></ArticleIdList></Reference><Reference><Citation>Staud R., Boissoneault J., Craggs J.G., Lai S., Robinson M.E. Task related cerebral blood flow changes of patients with chronic fatigue syndrome: an arterial spin labeling study. Fatigue. 2018;6:63&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5914525</ArticleId><ArticleId IdType="pubmed">29707427</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Julin P., Li T.-Q. Limbic perfusion is reduced in patients with Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Tomography. 2021;7:675&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8628916</ArticleId><ArticleId IdType="pubmed">34842817</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D.B., Light A.R., Light K.C., Broderick G., Shields M.R., Dougherty R.J., et al. Neural consequences of post-exertion malaise in Myalgic encephalomyelitis/chronic fatigue syndrome. Brain Behav Immun. 2017;62:87&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">28216087</ArticleId></ArticleIdList></Reference><Reference><Citation>Glassford J.A.G. The neuroinflammatory etiopathology of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Front Physiol. 2017;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5314655</ArticleId><ArticleId IdType="pubmed">28261110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay A., Tate W.P. A compromised paraventricular nucleus within a dysfunctional hypothalamus: a novel neuroinflammatory paradigm for ME/CFS. Int J Immunopathol Pharmacol. 2018;32 2058738418812342.</Citation></Reference><Reference><Citation>Maes M., Ringel K., Kubera M., Anderson G., Morris G., Galecki P., et al. In Myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. J Affect Disord. 2013;150:223&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">23664637</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan Z.Y., Barnden L.R., Kwiatek R.A., Bhuta S., Hermens D.F., Lagopoulos J. Neuroimaging characteristics of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review. J Transl Med. 2020;18:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7466519</ArticleId><ArticleId IdType="pubmed">32873297</ArticleId></ArticleIdList></Reference><Reference><Citation>Renz-Polster H., Tremblay M.-E., Bienzle D., Fischer J.E. The pathobiology of Myalgic encephalomyelitis/chronic fatigue syndrome: the case for neuroglial Failure. Frontiers in Cellular Neuroscience. 2022:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9124899</ArticleId><ArticleId IdType="pubmed">35614970</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnden L.R., Crouch B., Kwiatek R., Burnet R., Mernone A., Chryssidis S., et al. A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. NMR Biomed. 2011;24:1302&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369126</ArticleId><ArticleId IdType="pubmed">21560176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp J., Sunnquist M., Jason L.A., Newton J.L. Autonomic dysfunction in Myalgic encephalomyelitis and chronic fatigue syndrome: comparing self-report and objective measures. Clin Auton Res. 2019;29:475&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697554</ArticleId><ArticleId IdType="pubmed">31115729</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton J.L., Okonkwo O., Sutcliffe K., Seth A., Shin J., Jones D.E.J. Symptoms of autonomic dysfunction in chronic fatigue syndrome. QJM: An International Journal of Medicine. 2007;100:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">17617647</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler A.S., Blair D., Marsden J.T., Peters T.J., Wessely S., Cleare A.J. Autonomic function and serum erythropoietin levels in chronic fatigue syndrome. J Psychosom Res. 2004;56:179&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15016575</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph P., Arevalo C., Oliveira R.K.F., Faria-Urbina M., Felsenstein D., Oaklander A.L., et al. Insights from invasive cardiopulmonary exercise testing of patients with Myalgic encephalomyelitis/chronic fatigue syndrome. Chest. 2021;160:642&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727854</ArticleId><ArticleId IdType="pubmed">33577778</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph P., Pari R., Miller S., Warren A., Stovall M.C., Squires J., et al. Neurovascular dysregulation and acute exercise intolerance in Myalgic encephalomyelitis/chronic fatigue syndrome: a randomized. Placebo-Controlled Trial of Pyridostigmine Chest. 2022;162:1116&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pubmed">35526605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson M.J., Bahl J.S., Buckley J.D., Thomson R.L., Davison K. Evidence of altered cardiac autonomic regulation in Myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review and meta-analysis. Medicine (Baltimore) 2019;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6824690</ArticleId><ArticleId IdType="pubmed">31651868</ArticleId></ArticleIdList></Reference><Reference><Citation>Soboleva A., Mavropulo-Stolyarenko G., Karonova T., Thieme D., Hoehenwarter W., Ihling C., et al. Multiple glycation sites in blood plasma proteins as an integrated biomarker of type 2 diabetes mellitus. Int J Mol Sci. 2019;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6539793</ArticleId><ArticleId IdType="pubmed">31083443</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksu K., Donmez A., Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18:1478&#x2013;1493.</Citation><ArticleIdList><ArticleId IdType="pubmed">22364132</ArticleId></ArticleIdList></Reference><Reference><Citation>Branchford B.R., Carpenter S.L. The role of inflammation in venous thromboembolism. Front Pediatr. 2018;6:142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5974100</ArticleId><ArticleId IdType="pubmed">29876337</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanepoel A.C., Emmerson O., Pretorius E. Effect of progesterone and synthetic progestins on whole blood clot formation and erythrocyte structure. Microsc Microanal. 2017;23:607&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">28480839</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes Pires M.E., Clarke S.R., Marcondes S., Gibbins J.M. Lipopolysaccharide potentiates platelet responses via toll-like receptor 4-stimulated Akt-Erk-PLA2 signalling. PloS One. 2017;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5685579</ArticleId><ArticleId IdType="pubmed">29136006</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Li J., Ni H. Crosstalk between platelets and microbial pathogens. Front Immunol. 2020;11:1962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426443</ArticleId><ArticleId IdType="pubmed">32849656</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes J.M., Fillis T., Page M.J., Venter C., Lancry O., Kell D.B., et al. Gingipain R1 and lipopolysaccharide from Porphyromonas gingivalis have major effects on blood clot morphology and mechanics. Front Immunol. 2020;11:1551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7393971</ArticleId><ArticleId IdType="pubmed">32793214</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson L.O. Nondiscocytic erythrocytes in Myalgic encephalomyelitis. N Z Med J. 1989;102:126&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">2927808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L., de Barros B., Kingdon C.C., Cliff J.M., Clark T.G., Mudie K., et al. Evidence of clinical pathology abnormalities in people with Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) from an analytic cross-sectional study. Diagnostics. 2019;9:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6627354</ArticleId><ArticleId IdType="pubmed">30974900</ArticleId></ArticleIdList></Reference><Reference><Citation>Eccles J., Thompson C., Thompson B., Amato M., Themelis K., Critchley H., et al. AB1209&#xa0;mechanistic factors contributing to pain and fatigue in fibromyalgia and me/CFS: autonomic and inflammatory insights from an experimental medicine study. Ann Rheum Dis. 2022;81:1719.</Citation></Reference><Reference><Citation>Eccles J., Amato M., Thompson C., Themelis K., Critchley H., Harrison N., et al. AB0949&#xa0;autonomic and inflammatory mechanisms of pain and fatigue in fibromyalgia and ME/CFS: an interventional study. Ann Rheum Dis. 2020;79:1772.</Citation></Reference><Reference><Citation>Blauensteiner J., Bertinat R., Le&#xf3;n L.E., Riederer M., Sep&#xfa;lveda N., Westermeier F. Altered endothelial dysfunction-related miRs in plasma from ME/CFS patients. Sci Rep. 2021;11:10604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8134566</ArticleId><ArticleId IdType="pubmed">34011981</ArticleId></ArticleIdList></Reference><Reference><Citation>Cliff J.M., King E.C., Lee J.-S., Sep&#xfa;lveda N., Wolf A.-S., Kingdon C., et al. Cellular immune function in Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Front Immunol. 2019;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477089</ArticleId><ArticleId IdType="pubmed">31057538</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha A.K., Schmidt B.R., Wilhelmy J., Nguyen V., Abugherir A., Do J.K., et al. Red blood cell deformability is diminished in patients with chronic fatigue syndrome. Clin Hemorheol Microcirc. 2019;71:113&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6398549</ArticleId><ArticleId IdType="pubmed">30594919</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernow J., Mahdi A., Yang J., Zhou Z. Red blood cell dysfunction: a new player in cardiovascular disease. Cardiovasc Res. 2019;115:1596&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pubmed">31198931</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D., Berg L.H., Couvaras J., Harrison H. Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis. Blood Coagul Fibrinolysis. 1999;10:435&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">10695770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H., Hampton D., Marques de Menezes E.G., Deng X., Montoya J.G., Anderson J., et al. Comparative analysis of extracellular vesicles in patients with severe and mild Myalgic encephalomyelitis/chronic fatigue syndrome. Front Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8931328</ArticleId><ArticleId IdType="pubmed">35309313</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahanbani F., Maynard R.D., Sing J.C., Jahanbani S., Perrino J.J., Spacek D.V., et al. Phenotypic characteristics of peripheral immune cells of Myalgic encephalomyelitis/chronic fatigue syndrome via transmission electron microscopy: a pilot study. PloS One. 2022;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362953</ArticleId><ArticleId IdType="pubmed">35943990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy G., Norris G., Spence V., McLaren M., Belch J.J. Is chronic fatigue syndrome associated with platelet activation? Blood Coagul Fibrinolysis. 2006;17:89&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16479189</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarialiabad H., Taghrir M.H., Abdollahi A., Ghahramani N., Kumar M., Paydar S., et al. Long COVID, a comprehensive systematic scoping review. Infection. 2021;49:1163&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317481</ArticleId><ArticleId IdType="pubmed">34319569</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or Post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., Rivera S.C., McMullan C., Chandan J.S., et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114:428&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Twomey R., DeMars J., Franklin K., Culos-Reed S.N., Weatherald J., Wrightson J.G. Chronic fatigue and postexertional malaise in people living with Long COVID: an observational study. Phys Ther. 2022:102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383197</ArticleId><ArticleId IdType="pubmed">35079817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Venter C., Laubscher G.J., Kotze M.J., Oladejo S.O., Watson L.R., et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-acute sequelae of COVID-19 (PASC) Cardiovasc Diabetol. 2022;21:148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe9;cary S., Gaboury I., Poirier S., Garcia C., Simpson S., Bull M., et al. Humility and acceptance: working within our limits with Long COVID and Myalgic encephalomyelitis/chronic fatigue syndrome. J Orthop Sports Phys Ther. 2021;51:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">33930983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L., Drake T.M., Pauley E., Jesudason E.C., Olliaro P., Lim W.S., et al. Long Covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. Lancet Reg Health Eur. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Nkiliza A., Parks M., Cseresznye A., Oberlin S., Evans J.E., Darcey T., et al. Sex-specific plasma lipid profiles of ME/CFS patients and their association with pain, fatigue, and cognitive symptoms. J Transl Med. 2021;19:370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8401202</ArticleId><ArticleId IdType="pubmed">34454515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheema A.K., Sarria L., Bekheit M., Collado F., Almenar-P&#xe9;rez E., Mart&#xed;n-Mart&#xed;nez E., et al. Unravelling Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): gender-specific changes in the microRNA expression profiling in ME/CFS. J Cell Mol Med. 2020;24:5865&#x2013;5877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7214164</ArticleId><ArticleId IdType="pubmed">32291908</ArticleId></ArticleIdList></Reference><Reference><Citation>Capdevila L., Castro-Marrero J., Alegre J., Ramos-Castro J., Escorihuela R.M. Analysis of gender differences in HRV of patients with Myalgic encephalomyelitis/chronic fatigue syndrome using mobile-health technology. Sensors. 2021;21:3746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8197911</ArticleId><ArticleId IdType="pubmed">34071326</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvester S.V., Rusu R., Chan B., Bellows M., O&#x2019;Keefe C., Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin. 2022;38:1391&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pubmed">35726132</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam W. Hypercoagulability in COVID-19: a review of the potential mechanisms underlying clotting disorders. SAGE Open Med. 2021;9 20503121211002996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989108</ArticleId><ArticleId IdType="pubmed">33815798</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakura H., Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648664</ArticleId><ArticleId IdType="pubmed">33161508</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L., Benigni A., Casiraghi F., Ng L.F.P., Renia L., Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17:46&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemetski S.M., Ip A., Josephs J., Hellmann M. Clotting events among hospitalized patients infected with COVID-19 in a large multisite cohort in the United States. PloS One. 2022;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8730413</ArticleId><ArticleId IdType="pubmed">34986205</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Bakky M.S., Amin E., Ewees M.G., Mahmoud N.I., Mohammed H.A., Altowayan W.M., et al. Coagulation system activation for targeting of COVID-19: insights into anticoagulants, vaccine-loaded nanoparticles, and hypercoagulability in COVID-19 vaccines. Viruses. 2022:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8876839</ArticleId><ArticleId IdType="pubmed">35215822</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J., et al. Persistent clotting protein pathology in long COVID/Post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20:172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Prog Biophys Mol Biol. 2017;123:16&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">27554450</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Venter C., Vlok M., Ngoepe M., Laubscher G.J., Lourens P.J., et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci Rep. 2021;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Mbotwe S., Bester J., Robinson C.J., Kell D.B. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. J R Soc Interface. 2016;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5046953</ArticleId><ArticleId IdType="pubmed">27605168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. No effects without causes: the iron dysregulation and dormant microbes hypothesis for chronic, inflammatory diseases. Biol Rev Camb Philos Soc. 2018;93:1518&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6055827</ArticleId><ArticleId IdType="pubmed">29575574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu J.K., Sozmen E.G., Dixit K., Montano M., Matsui Y., Liu Y., et al. SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. bioRxiv. 2021</Citation></Reference><Reference><Citation>&#xd8;stergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Miszta A., Huskens D., Donkervoort D., Roberts M.J.M., Wolberg A.S., de Laat B. Assessing plasmin generation in health and disease. Int J Mol Sci. 2021;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963172</ArticleId><ArticleId IdType="pubmed">33803235</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Page M.J., Hendricks L., Nkosi N.B., Benson S.R., Kell D.B. Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel AmytrackerTM stains. J R Soc Interface. 2018;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832738</ArticleId><ArticleId IdType="pubmed">29445039</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Mbotwe S., Kell D.B. Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities. Sci Rep. 2017;7:9680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574907</ArticleId><ArticleId IdType="pubmed">28851981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen) Integr Biol (Camb) 2015;7:24&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25335120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bester J., Soma P., Kell D.B., Pretorius E. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS) Oncotarget. 2015;6:35284&#x2013;35303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742105</ArticleId><ArticleId IdType="pubmed">26462180</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Venter C., Laubscher G., Kotze M., Moremi K., Oladejo S., et al. 2021. Combined triple treatment of fibrin amyloid microclots and platelet pathology in individuals with Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) can resolve their persistent symptoms.</Citation></Reference><Reference><Citation>Odrljin T.M., Francis C.W., Sporn L.A., Bunce L.A., Marder V.J., Simpson-Haidaris P.J. Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vasc Biol. 1996;16:1544&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pubmed">8977460</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahni A., Francis C.W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood. 2000;96:3772&#x2013;3778.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090059</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J., Ferber A., Bach T.L., Yaen C.H. Interaction of fibrin with VE-cadherin. Ann N Y Acad Sci. 2001;936:386&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11460494</ArticleId></ArticleIdList></Reference><Reference><Citation>Drabik D., Chodaczek G., Kraszewski S. Effect of amyloid-&#x3b2; monomers on lipid membrane mechanical parameters-potential implications for mechanically driven neurodegeneration in Alzheimer&#x2019;s disease. Int J Mol Sci. 2020;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792773</ArticleId><ArticleId IdType="pubmed">33375009</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertinat R., Villalobos-Labra R., Hofmann L., Blauensteiner J., Sepulveda N., Westermeier F. Decreased NO production in endothelial cells exposed to plasma from ME/CFS patients. Vascul Pharmacol. 2022;143</Citation><ArticleIdList><ArticleId IdType="pubmed">35074481</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaskamp L., Roubal C., Uddin S., Sotzny F., Kedor C., Bauer S., et al. Serum of Post-COVID-19 syndrome patients with or without ME/CFS differentially affects endothelial cell function in vitro. Cells. 2022:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9367589</ArticleId><ArticleId IdType="pubmed">35954219</ArticleId></ArticleIdList></Reference><Reference><Citation>Corban M.T., Lerman L.O., Lerman A. Endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2019;39:1272&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">31242027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H.J., Wu Z.Y., Nie X.W., Bian J.S. Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide. Front Pharmacol. 2019;10:1568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985156</ArticleId><ArticleId IdType="pubmed">32038245</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyers C.M., Miller F.J. Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci. 2014;15:11324&#x2013;11349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139785</ArticleId><ArticleId IdType="pubmed">24968272</ArticleId></ArticleIdList></Reference><Reference><Citation>Girouard H., Park L., Anrather J., Zhou P., Iadecola C. Cerebrovascular Nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2007;27:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">17138940</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz E., Gori T., M&#xfc;nzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34:665&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">21512515</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyauchi T., Sakai S. Endothelin and the heart in health and diseases. Peptides. 2019;111:77&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">30352269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaoukis A., Deftereos S., Raisakis K., Giannopoulos G., Bouras G., Panagopoulou V., et al. The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition. Curr Top Med Chem. 2013;13:95&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">23470073</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuyun M.F., Ng L.L., Ng G.A. Endothelial dysfunction, endothelial nitric oxide bioavailability, tetrahydrobiopterin, and 5-methyltetrahydrofolate in cardiovascular disease. Where are we with therapy? Microvasc Res. 2018;119:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">29596860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasdai D., Gibbons R.J., Holmes D.R., Higano S.T., Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 1997;96 3390&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9396432</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallet B. Endothelial cell dysfunction and abnormal tissue perfusion. Crit Care Med. 2002;30 S229&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">12004241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriilaki E., Eftychidis I., Papassotiriou I. Update on endothelial dysfunction in COVID-19: severe disease, long COVID-19 and pediatric characteristics. Journal of Laboratory Medicine. 2021;45:293&#x2013;302.</Citation></Reference><Reference><Citation>Ambrosino P., Calcaterra I., Molino A., Moretta P., Lupoli R., Spedicato G.A., et al. Persistent endothelial dysfunction in Post-acute COVID-19 syndrome: a case-control study. Biomedicines. 2021;9:957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391623</ArticleId><ArticleId IdType="pubmed">34440161</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomou E., Souvaliotis N., Lampsas S., Siasos G., Poulakou G., Theofilis P., et al. Endothelial dysfunction in acute and long standing COVID&#x2212;19: a prospective cohort study. Vascul Pharmacol. 2022;144</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893931</ArticleId><ArticleId IdType="pubmed">35248780</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S., Ibnhadjamor H., Jdidi J., Torjmen S., Kraiem S., Bahloul A., et al. Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with Long-COVID-19: insights from TUN-EndCOV study. Front Cardiovasc Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9133483</ArticleId><ArticleId IdType="pubmed">35647070</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu S.X., Tyagi T., Jain K., Gu V.W., Lee S.H., Hwa J.M., et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021;18:194&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675396</ArticleId><ArticleId IdType="pubmed">33214651</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S., Ibn Hadj Amor H., Jdidi J., Torjmen S., Kraiem S., Hammami R., et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Frontiers in Cardiovascular Medicine. 2021:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosato M., Calvani R., Picca A., Ciciarello F., Galluzzo V., Coelho-J&#xfa;nior H.J., et al. Effects of l-arginine plus vitamin C supplementation on physical performance, endothelial function, and persistent fatigue in adults with Long COVID: a single-blind randomized controlled trial. Nutrients. 2022;14:4984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9738241</ArticleId><ArticleId IdType="pubmed">36501014</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimarco V., Izzo R., Mone P., Trimarco B., Santulli G. Targeting endothelial dysfunction and oxidative stress in Long-COVID. Pharmacol Res. 2022;184</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9467917</ArticleId><ArticleId IdType="pubmed">36108875</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rland K., Sandvik M.K., Rekeland I.G., Ribu L., Sm&#xe5;stuen M.C., Mella O., et al. Reduced endothelial function in Myalgic encephalomyelitis/chronic fatigue syndrome-results from open-label cyclophosphamide intervention study. Front Med (Lausanne). 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019750</ArticleId><ArticleId IdType="pubmed">33829023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F., Blanco J., Capelli E., Castro-Marrero J., Steiner S., Murovska M., et al. Myalgic encephalomyelitis/chronic fatigue syndrome - evidence for an autoimmune disease. Autoimmun Rev. 2018;17:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">29635081</ArticleId></ArticleIdList></Reference><Reference><Citation>Arreola-Diaz R., Majluf-Cruz A., Sanchez-Torres L., Hernandez-Juarez J. The pathophysiology of the antiphospholipid syndrome: a perspective from the blood coagulation system. Clin Appl Thromb Hemost. 2022;28 10760296221088576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950029</ArticleId><ArticleId IdType="pubmed">35317658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoval Y.H., Atef M.E., Levesque L.O., Li Y., Anand-Srivastava M.B. Endothelin-1 signaling in vascular physiology and pathophysiology. Curr Vasc Pharmacol. 2014;12:202&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">24568156</ArticleId></ArticleIdList></Reference><Reference><Citation>Massardo T., Quintana J.C., Jaimovich R., S&#xe1;ez C.G., Risco L., Liberman C., et al. Regional brain perfusion is associated with endothelial dysfunction markers in major depressive disorder. Neuropsychobiology. 2021;80:214&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">32726779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandvik M.K., S&#xf8;rland K., Leirgul E., Rekeland I.G., Stavland C.S., Mella O., et al. Endothelial dysfunction in ME/CFS patients. PloS One. 2023;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9894436</ArticleId><ArticleId IdType="pubmed">36730360</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy B.I., Schiffrin E.L., Mourad J.-J., Agostini D., Vicaut E., Safar M.E., et al. Impaired tissue perfusion. Circulation. 2008;118:968&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">18725503</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanculescu D., Bergquist J. Perspective: drawing on findings from critical illness to explain Myalgic encephalomyelitis/chronic fatigue syndrome. Front Med (Lausanne). 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957276</ArticleId><ArticleId IdType="pubmed">35345768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J. Early growth response gene upregulation in Epstein-Barr virus (EBV)-associated Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Biomolecules. 2020:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7692278</ArticleId><ArticleId IdType="pubmed">33114612</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe R.P., Kozlova E.V., Yetman D.L., Walling D.M., Goodwin J.S., Glaser R. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol. 2007;42:563&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1992441</ArticleId><ArticleId IdType="pubmed">17337145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney B.V., Crucian B.E., Pierson D.L., Laudenslager M.L., Mehta S.K. Herpes virus reactivation in astronauts during spaceflight and its application on earth. Front Microbiol. 2019;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6374706</ArticleId><ArticleId IdType="pubmed">30792698</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J.I. Herpesvirus latency. J Clin Invest. 2020;130:3361&#x2013;3369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324166</ArticleId><ArticleId IdType="pubmed">32364538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalla M., Hammerschmidt W. Human B cells on their route to latent infection &#x2013; early but transient expression of lytic genes of Epstein-Barr virus. Eur J Cell Biol. 2012;91:65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">21450364</ArticleId></ArticleIdList></Reference><Reference><Citation>Price A.M., Luftig M.A. In: Advances in virus research. Maramorosch K., Murphy F.A., editors. Academic Press; 2014. Chapter six - dynamic Epstein&#x2013;Barr virus gene expression on the path to B-cell transformation; pp. 279&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911173</ArticleId><ArticleId IdType="pubmed">24373315</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo R., Liang J.H., Zhang Y., Lutchenkov M., Li Z., Wang Y., et al. Methionine metabolism controls the B cell EBV epigenome and viral latency. Cell Metab. 2022;34 1280&#x2013;97.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482757</ArticleId><ArticleId IdType="pubmed">36070681</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner-Glunde M., Kruminis-Kaszkiel E., Savanagouder M. Herpesviral latency&#x2014;common themes. Pathogens. 2020;9:125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167855</ArticleId><ArticleId IdType="pubmed">32075270</ArticleId></ArticleIdList></Reference><Reference><Citation>Grey F. Role of microRNAs in herpesvirus latency and persistence. J Gen Virol. 2015;96:739&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">25406174</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata T., Sugimoto A., Inagaki T., Yanagi Y., Watanabe T., Sato Y., et al. Molecular basis of Epstein&#x2013;Barr virus latency establishment and lytic reactivation. Viruses. 2021;13:2344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8706188</ArticleId><ArticleId IdType="pubmed">34960613</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., Okyay R.A., Licht W.E., Hurley D.J. Investigation of Long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Song J., Dai L., Post S.R., Qin Z. SARS-CoV-2 infection and lytic reactivation of herpesviruses: a potential threat in the postpandemic era? J Med Virol. 2022;94:5103&#x2013;5111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350099</ArticleId><ArticleId IdType="pubmed">35819034</ArticleId></ArticleIdList></Reference><Reference><Citation>Maple P.A.C. COVID-19, SARS-CoV-2 vaccination, and human herpesviruses infections. Vaccines. 2023;11:232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9963083</ArticleId><ArticleId IdType="pubmed">36851110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M., Paiva B., Montero-Mateo R., Garcia N., Zabaleta A. Epstein-Barr virus and the origin of Myalgic encephalomyelitis or chronic fatigue syndrome. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634673</ArticleId><ArticleId IdType="pubmed">34867935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J.R. Epstein-Barr virus induced Gene-2 upregulation identifies a particular subtype of chronic fatigue syndrome/Myalgic encephalomyelitis. Front Pediatr. 2019;7:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6424879</ArticleId><ArticleId IdType="pubmed">30918887</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkenbach M., Josefsen K., Yalamanchili R., Lenoir G., Kieff E. Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J Virol. 1993;67:2209&#x2013;2220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240341</ArticleId><ArticleId IdType="pubmed">8383238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensah F., Bansal A., Berkovitz S., Sharma A., Reddy V., Leandro M.J., et al. Extended B cell phenotype in patients with Myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study. Clin Exp Immunol. 2016;184:237&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4837232</ArticleId><ArticleId IdType="pubmed">26646713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley A.S., Ford B., Bansal A.S. Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Exp Immunol. 2013;172:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719933</ArticleId><ArticleId IdType="pubmed">23480187</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen C.B., Als&#xf8;e L., Lindvall J.M., Sulheim D., Fagermoen E., Winger A., et al. Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival. J Transl Med. 2017;15:102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5426002</ArticleId><ArticleId IdType="pubmed">28494812</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner S., Becker S.C., Hartwig J., Sotzny F., Lorenz S., Bauer S., et al. Autoimmunity-related risk variants in PTPN22 and CTLA4 are associated with ME/CFS with infectious onset. Front Immunol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161310</ArticleId><ArticleId IdType="pubmed">32328064</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluge &#xd8;., Risa K., Lunde S., Alme K., Rekeland I.G., Sapkota D., et al. B-lymphocyte depletion in Myalgic encephalopathy/ chronic fatigue syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment PLOS ONE. 2015;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4488509</ArticleId><ArticleId IdType="pubmed">26132314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablashi D.V., Eastman H.B., Owen C.B., Roman M.M., Friedman J., Zabriskie J.B., et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol. 2000;16:179&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">10738137</ArticleId></ArticleIdList></Reference><Reference><Citation>Manian F.A. Simultaneous measurement of antibodies to Epstein-Barr virus, human herpesvirus 6, herpes simplex virus types 1 and 2, and 14 enteroviruses in chronic fatigue syndrome: is there evidence of activation of a nonspecific polyclonal immune response? Clin Infect Dis. 1994;19:448&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">7811864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A.M., Beqaj S.H., Deeter R.G., Fitzgerald J.T. IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo. 2002;16:153&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">12182109</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J., Rizwan M., B&#xf6;hlin-Wiener A., Elfaitouri A., Julin P., Zachrisson O., et al. Antibodies to human herpesviruses in Myalgic encephalomyelitis/chronic fatigue syndrome patients. Front Immunol. 2019;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6702656</ArticleId><ArticleId IdType="pubmed">31475007</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin P., Williams M.V., Klimas N.G., Fletcher M.A., Barnes Z., Ariza M.E. Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war illness patients exhibit increased humoral responses to the herpesviruses-encoded dUTPase: implications in disease pathophysiology. J Med Virol. 2017;89:1636&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5513753</ArticleId><ArticleId IdType="pubmed">28303641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa-Dzelzkaleja S., Krumina A., Capenko S., Nora-Krukle Z., Gravelsina S., Vilmane A., et al. The persistent viral infections in the development and severity of Myalgic encephalomyelitis/chronic fatigue syndrome. J Transl Med. 2023;21:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847171</ArticleId><ArticleId IdType="pubmed">36653846</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues T.D., Grabowska A.D., Lee J.-S., Ameijeiras-Alonso J., Westermeier F., Scheibenbogen C., et al. Herpesviruses serology distinguishes different subgroups of patients from the United Kingdom Myalgic encephalomyelitis/chronic fatigue syndrome biobank. Front Med. 2021:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287507</ArticleId><ArticleId IdType="pubmed">34291062</ArticleId></ArticleIdList></Reference><Reference><Citation>Maltsev D. A comparative study of valaciclovir, valganciclovir, and artesunate efficacy in reactivated HHV-6 and HHV-7 infections associated with chronic fatigue syndrome/Myalgic encephalomyelitis. Microbiol Immunol. 2022;66:193&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">35102619</ArticleId></ArticleIdList></Reference><Reference><Citation>De Pelsmaeker S., Romero N., Vitale M., Favoreel H.W. Herpesvirus evasion of natural killer cells. J Virol. 2018;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5952149</ArticleId><ArticleId IdType="pubmed">29540598</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldman W.J., Williams M.V., Lemeshow S., Binkley P., Guttridge D., Kiecolt-Glaser J.K., et al. Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: evidence for depression-induced atherosclerotic risk. Brain Behav Immun. 2008;22:215&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2245868</ArticleId><ArticleId IdType="pubmed">17845840</ArticleId></ArticleIdList></Reference><Reference><Citation>Krstanovi&#x107; F., Britt W.J., Jonji&#x107; S., Brizi&#x107; I. Cytomegalovirus infection and inflammation in developing brain. Viruses. 2021;13:1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8227981</ArticleId><ArticleId IdType="pubmed">34200083</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso A., Rotola A., Comar M., Favilli F., Galvan M., Tosetti M., et al. HHV-6 infects human aortic and heart microvascular endothelial cells, increasing their ability to secrete proinflammatory chemokines. J Med Virol. 2002;67:528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12115999</ArticleId></ArticleIdList></Reference><Reference><Citation>Alibek K., Baiken Y., Kakpenova A., Mussabekova A., Zhussupbekova S., Akan M., et al. Implication of human herpesviruses in oncogenesis through immune evasion and supression. Infectious Agents and Cancer. 2014;9:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904197</ArticleId><ArticleId IdType="pubmed">24438207</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge R., Sartor M.L., Scott F., Cleare A.J. Inflammatory proteins are altered in chronic fatigue syndrome-a systematic review and meta-analysis. Neurosci Biobehav Rev. 2019;107:69&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">31465778</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N., du Preez S., Cabanas H., Staines D., Marshall-Gradisnik S. A systematic review of natural killer cells profile and cytotoxic function in Myalgic encephalomyelitis/chronic fatigue syndrome. Syst Rev. 2019;8:279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6857215</ArticleId><ArticleId IdType="pubmed">31727160</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamoorthy S., Honn K.V. Inflammation and disease progression. Cancer and Metastasis Reviews. 2006;25:481&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">17103050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotas Maya E., Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell. 2015;160:816&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369762</ArticleId><ArticleId IdType="pubmed">25723161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2020;33:127&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799025</ArticleId><ArticleId IdType="pubmed">33337480</ArticleId></ArticleIdList></Reference><Reference><Citation>Carod-Artal F.J. Infectious diseases causing autonomic dysfunction. Clin Auton Res. 2018;28:67&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">28730326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.H., Garber D.A., Schaffer P.A., Knipe D.M., Coen D.M. Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivation. Virology. 2000;278:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11112495</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner I., Benninger F. Update on herpes virus infections of the nervous system. Curr Neurol Neurosci Rep. 2013;13:414.</Citation><ArticleIdList><ArticleId IdType="pubmed">24142852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilden D.H., Mahalingam R., Cohrs R.J., Tyler K.L. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol. 2007;3:82&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17279082</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpi A. Epstein-Barr virus and human herpesvirus type 8 infections of the central nervous system. Herpes. 2004;11(Suppl. 2) 120A-7A.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett J.L., Mahalingam R., Wellish M.C., Gilden D.H. Epstein-barr virus&#x2013;associated acute autonomic neuropathy. Ann Neurol. 1996;40:453&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797536</ArticleId></ArticleIdList></Reference><Reference><Citation>Corssmit E.P.M., Leverstein-Van Hall M.A., Portegies P., Bakker P. Case report severe neurological complications in association with Epstein-Barr virus infection. J Neurovirol. 1997;3:460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475119</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii N., Tabira T., Shibasaki H., Kuroiwa Y., Ohnishi A., Nagaki J. Acute autonomic and sensory neuropathy associated with elevated Epstein-Barr virus antibody titre. J Neurol Neurosurg Psychiatry. 1982;45:656&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC491485</ArticleId><ArticleId IdType="pubmed">6288883</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodig D., Ngo M., Bailey D., Bril V. Brachial plexopathy complicating Epstein-Barr virus infection in an adult. Acta Myol. 2010;29:357&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040589</ArticleId><ArticleId IdType="pubmed">21314019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejima M., Ota K., Yamamoto K., Sugishita Y., Maruyama S. A case of acute pandysautonomia and diffuse brain stem impairment associated with EB virus infection. Rinsho Shinkeigaku. 1994;34:1136&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">7729095</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y., Oishi T., Ohnishi A., Murai Y., Imawatari R. Acute cerebellar ataxia with sympathotonic orthostatic hypotension following Epstein-Barr virus infection--a case report. Rinsho Shinkeigaku. 1993;33:503&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">8395987</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz B.Z., Stewart J.M., Shiraishi Y., Mears C.J., Taylor R. Autonomic symptoms at baseline and following infectious mononucleosis in a prospective cohort of adolescents. Arch Pediatr Adolesc Med. 2011;165:765&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896070</ArticleId><ArticleId IdType="pubmed">21810640</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams Ph D.M., Cox B., Lafuse Ph D.W., Ariza M.E. Epstein-Barr virus dUTPase induces neuroinflammatory mediators: implications for Myalgic encephalomyelitis/chronic fatigue syndrome. Clin Ther. 2019;41:848&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525645</ArticleId><ArticleId IdType="pubmed">31040055</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida Y., Koike H., Oguri T., Kato H., Yuasa H., Mitake S. Successful corticosteroid therapies in a case of acute motor, sensory, autonomic neuropathy after cytomegalovirus infection. Rinsho Shinkeigaku. 2015;55:339&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26028197</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakao K., Namekawa M., Kondo S., Ono S., Nakano I. Subacute autonomic and sensory neuropathy closely related to cytomegalovirus infection preceded by frequent syncopal attacks. Rinsho Shinkeigaku. 2016;56:555&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477575</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes L., Theunissen K., Schepers S., Indesteege I., Delmotte K. Acute autonomic dysregulation due to HHV-6 encephalitis in an immunocompromised patient: a case report and literature review. Acta Neurol Belg. 2022;122:583&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">35349121</ArticleId></ArticleIdList></Reference><Reference><Citation>Shouman K., Vanichkachorn G., Cheshire W.P., Suarez M.D., Shelly S., Lamotte G.J., et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res. 2021;31:385&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8050227</ArticleId><ArticleId IdType="pubmed">33860871</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J., Scorza F.A., Scorza C., Fiorini A. COVID-19 associated cranial nerve neuropathy: a systematic review. Bosn J Basic Med Sci. 2022;22:39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8860318</ArticleId><ArticleId IdType="pubmed">34392827</ArticleId></ArticleIdList></Reference><Reference><Citation>Senini V., Amara U., Paul M., Kim H. Porphyromonas gingivalis lipopolysaccharide activates platelet Cdc42 and promotes platelet spreading and thrombosis. J Periodontol. 2019;90:1336&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">31106406</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch L., Hofer S., Weigand M.A., Frommhold D., Poeschl J. Lipopolysaccharide-induced activation of coagulation in neonatal cord and adult blood monitored by thrombelastography. Thromb Res. 2009;124:463&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">19477486</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch A., Meesters M.I., Scheller B., Boer C., Zacharowski K. Systemic endotoxin activity correlates with clot formation: an observational study in patients with early systemic inflammation and sepsis. Crit Care. 2013;17:R198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057518</ArticleId><ArticleId IdType="pubmed">24025340</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Kruger A., Venter C., Burger E.M., Laubscher G.J., Maponga T.G., et al. Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost. 2022;48:858&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">36174604</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapp S., von Aulock S., Leendertse M., Haslinger I., Draing C., Golenbock D.T., et al. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. The Journal of Immunology. 2008;180:3478&#x2013;3484.</Citation><ArticleIdList><ArticleId IdType="pubmed">18292574</ArticleId></ArticleIdList></Reference><Reference><Citation>Beachey E.H., Chiang T.M., Ofek I., Kang A.H. Interaction of lipoteichoic acid of group a streptococci with human platelets. Infect Immun. 1977;16:649&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC421005</ArticleId><ArticleId IdType="pubmed">324916</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay D.G., Margaretten W. Disseminated intravascular coagulation in virus diseases. Arch Intern Med. 1967;120:129&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">4952942</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.-H., Liu C.-C., Wang S.-T., Lei H.-Y., Liu H.-S., Lin Y.-S., et al. Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol. 2001;63:247&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">11170065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N., Antoniak S., Wolberg A.S., Kasthuri R., Key N.S. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler Thromb Vasc Biol. 2020;40:2033&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7447001</ArticleId><ArticleId IdType="pubmed">32657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaujac C., Boukour S., Cramer-Bord&#xe9; E. Platelets and viruses: an ambivalent relationship. Cell Mol Life Sci. 2010;67:545&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11115580</ArticleId><ArticleId IdType="pubmed">20012669</ArticleId></ArticleIdList></Reference><Reference><Citation>Assinger A. Platelets and infection &#x2013; an emerging role of platelets in viral infection. Front Immunol. 2014;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270245</ArticleId><ArticleId IdType="pubmed">25566260</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Liu Y., Wang X., Yang L., Li H., Wang Y., et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020;13:120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471641</ArticleId><ArticleId IdType="pubmed">32887634</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M., Bottino N., Tagliabue P., Grasselli G., Novembrino C., Chantarangkul V., et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18:1738&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S., Hammarstr&#xf6;m P. Amyloidogenesis of SARS-CoV-2 spike protein. J Am Chem Soc. 2022;144:8945&#x2013;8950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9136918</ArticleId><ArticleId IdType="pubmed">35579205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershom E.S., Sutherland M.R., Lollar P., ELG Pryzdial. Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation. J Thromb Haemost. 2010;8:1037&#x2013;1043.</Citation><ArticleIdList><ArticleId IdType="pubmed">20128864</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson A.C., Hajjar D.P. Herpesviruses and thrombosis: activation of coagulation on the endothelium. Clin Chim Acta. 1999;286:23&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">10511282</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland M.R., Raynor C.M., Leenknegt H., Wright J.F., Pryzdial E.L. Coagulation initiated on herpesviruses. Proc Natl Acad Sci U S A. 1997;94:13510&#x2013;13514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28336</ArticleId><ArticleId IdType="pubmed">9391056</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steijn J.H.M., van Tol K.M., van Essen L.H., Gans R.O.B. Disseminated intravascular coagulation as an unusual presentation of an Epstein&#x2013;Barr virus infection. Neth J Med. 2000;57:169&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">11006494</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor D.S., Elmariah S., Aledort L.M., Pinney S.P. Disseminated intravascular coagulation complicating Epstein-Barr virus infection in a cardiac transplant recipient: a case report. Transplant Proc. 2010;42:1973&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">20620559</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovi&#x107; M., Smiljani&#x107; K., Dobutovi&#x107; B., Syrovets T., Simmet T., Isenovi&#x107; E.R. Human cytomegalovirus infection and atherothrombosis. J Thromb Thrombolysis. 2012;33:160&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">22161772</ArticleId></ArticleIdList></Reference><Reference><Citation>Squizzato A., Gerdes V.E., B&#xfc;ller H.R. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost. 2005;93:403&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">15735787</ArticleId></ArticleIdList></Reference><Reference><Citation>Humblot S., Martin T., Pasquali J.-L., Korganow A.-S. Blood coagulation disorders during primary cytomegalovirus infection. Arch Intern Med. 2001;161:2149&#x2013;2150.</Citation><ArticleIdList><ArticleId IdType="pubmed">11570949</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryzdial E.L.G., Wright J.F. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid. Blood. 1994;84:3749&#x2013;3757.</Citation><ArticleIdList><ArticleId IdType="pubmed">7949131</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam-Mieras M.C., Muller A.D., van Hinsbergh V.W., Mullers W.J., Bomans P.H., Bruggeman C.A. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost. 1992;68:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">1332211</ArticleId></ArticleIdList></Reference><Reference><Citation>Assinger A., Kral J.B., Yaiw K.C., Schrottmaier W.C., Kurzejamska E., Wang Y., et al. Human cytomegalovirus&#x2013;platelet interaction triggers toll-like receptor 2&#x2013;dependent proinflammatory and proangiogenic responses. Arterioscler Thromb Vasc Biol. 2014;34:801&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">24558109</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad A., Menezes J. Binding of the Epstein-Barr virus to human platelets causes the release of transforming growth factor-beta. J Immunol. 1997;159:3984&#x2013;3988.</Citation><ArticleIdList><ArticleId IdType="pubmed">9378987</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X., Chen H., Zhou X., Liu P., Zhang X., Zhu Q., et al. EBV infection in epithelial malignancies induces resistance to antitumor natural killer cells via F3-mediated platelet aggregation. Cancer Res. 2022;82:1070&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">35064016</ArticleId></ArticleIdList></Reference><Reference><Citation>Agbanyo F.R., Wasi S. Human cytomegalovirus interaction with platelets and adhesive glycoproteins: significance in viral pathogenesis. J Infect Dis. 1994;170:1120&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">7963703</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzilieris-Petras G., Lai X., Rashidi A.S., Verjans G., Reinert L.S., Paludan S.R. Microglia activate early antiviral responses upon herpes simplex virus 1 entry into the brain to counteract development of encephalitis-like disease in mice. J Virol. 2022;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941881</ArticleId><ArticleId IdType="pubmed">35045263</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrycy M., Chodkowski M., Krzyzowska M. Role of microglia in herpesvirus-related Neuroinflammation and neurodegeneration. Pathogens. 2022;11:809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9324537</ArticleId><ArticleId IdType="pubmed">35890053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassani A., Corboy J.R., Al-Salam S., Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PloS One. 2018;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5796799</ArticleId><ArticleId IdType="pubmed">29394264</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob H.S., Visser M., Key N.S., Goodman J.L., Moldow C.F., Vercellotti G.M. Herpes virus infection of endothelium: new insights into atherosclerosis. Trans Am Clin Climatol Assoc. 1992;103:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376689</ArticleId><ArticleId IdType="pubmed">1329303</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor-Wiedeman J., Sissons J.G., Borysiewicz L.K., Sinclair J.H. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991;72(Pt 9):2059&#x2013;2064.</Citation><ArticleIdList><ArticleId IdType="pubmed">1654370</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;derberg-Naucl&#xe9;r C., Fish K.N., Nelson J.A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">9335340</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A., Marshall T. Myalgic encephalomyelitis/chronic fatigue syndrome in the era of the human microbiome: persistent pathogens drive chronic symptoms by interfering with host metabolism, gene expression, and immunity. Front Pediatr. 2018;6:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288442</ArticleId><ArticleId IdType="pubmed">30564562</ArticleId></ArticleIdList></Reference><Reference><Citation>Deumer U.S., Varesi A., Floris V., Savioli G., Mantovani E., L&#xf3;pez-Carrasco P., et al. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): an overview. J Clin Med. 2021:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8538807</ArticleId><ArticleId IdType="pubmed">34682909</ArticleId></ArticleIdList></Reference><Reference><Citation>Siberry V.G.R., Rowe P.C. Pediatric Long COVID and Myalgic encephalomyelitis/chronic fatigue syndrome: overlaps and opportunities. Pediatr Infect Dis J. 2022;41 e139-e41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919937</ArticleId><ArticleId IdType="pubmed">35121715</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>McCully K.K., Natelson B.H. Impaired oxygen delivery to muscle in chronic fatigue syndrome. Clin Sci (Lond) 1999;97 603&#x2013;8; discussion 11&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">10545311</ArticleId></ArticleIdList></Reference><Reference><Citation>McCully K.K., Smith S., Rajaei S., Leigh J.S., Jr., Natelson B.H. Muscle metabolism with blood flow restriction in chronic fatigue syndrome. J Appl Physiol. 1985;2004(96):871&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680353</ArticleId><ArticleId IdType="pubmed">14578362</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherbakov N., Szklarski M., Hartwig J., Sotzny F., Lorenz S., Meyer A., et al. Peripheral endothelial dysfunction in Myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Fail. 2020;7:1064&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261521</ArticleId><ArticleId IdType="pubmed">32154656</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>